Daily News Day 2 coverage includes expert commentary on studies presented during Sunday's Clinical Trials and Innovation Session, a preview of today's Keynote and this afternoon's Plenary Session and much more!
SABR-5 trial confirms low risk of high grade toxicity for treatment of oligometastases with SABR
Phase II/III randomized trial CONCORDE (PRODIGE-26) fails to find benefit to dose-escalated definitive chemoradiotherapy in esophageal cancer
PROs from NRG/RTOG 0815
Short-term androgen deprivation therapy causes a significant but self-limited decrement in patient-reported outcomes
Stage 3 NSCLC
Combined Checkpoint Blockade Inhibition and Concurrent Chemoradiation Therapy in Stage 3 Non-small Cell Lung Cancer: A Bridge Too Far?
ADT with RT for Prostate
Should androgen deprivation therapy be used with radiation therapy in prostate cancer treatment?